Sanofi Looks To Hanmi Deal To Bolster Diabetes Franchise
This article was originally published in Scrip
Executive Summary
Just a week after Sanofi admitted sales of its diabetes franchise are set to decline over the next three years, it has announced a licensing deal with Korean firm Hanmi Pharmaceuticals for its long-acting diabetes products worth €400m up front.